This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.bbc.co.uk/news/health-50144742
The article has changed 7 times. There is an RSS feed of changes available.
Version 1 | Version 2 |
---|---|
Cystic fibrosis drug given green light in England | Cystic fibrosis drug given green light in England |
(32 minutes later) | |
A life-extending drug for cystic fibrosis will be available on the NHS in England, health bosses say. | A life-extending drug for cystic fibrosis will be available on the NHS in England, health bosses say. |
NHS England reached a deal with Orkambi manufacturers Vertex Pharmaceuticals after months of talks. Patients should be able to get the drug within 30 days. | |
The drug improves lung function and reduces breathing difficulties and can be given to children as young as two. | |
The firm wanted to charge £100,000 per patient per year but a compromise has been reached in a confidential deal. | |
It is understood to involve significantly less than the sum originally asked for. | |
'Best present' | |
Patients and campaigners have expressed delight at the announcement. | |
Christina Walker said it meant her son, Luis, eight, should be on it by Christmas, calling it the "best present ever". | |
"I can't stop smiling. I'm overwhelmingly happy. It's absolutely wonderful," she said. | |
The deal comes after the Scottish Government reached an agreement with the manufacturers last month. | |
Wales and Northern Ireland can now also access the drug under the same terms negotiated by NHS England. | |
'Patients and taxpayers' | |
Two other drugs made by Vertex - Symkevi and Kalydeco - will be made available as part of the deal. | Two other drugs made by Vertex - Symkevi and Kalydeco - will be made available as part of the deal. |
These also treat cystic fibrosis symptoms but cannot be used until a patient is 12. | |
The treatments do not work for all patients with cystic fibrosis - only those with certain mutations. | The treatments do not work for all patients with cystic fibrosis - only those with certain mutations. |
It is estimated about half of the 10,000 patients in the UK will benefit from these drugs. | It is estimated about half of the 10,000 patients in the UK will benefit from these drugs. |
Cystic fibrosis is a life-shortening genetic condition that causes fatal lung damage. | Cystic fibrosis is a life-shortening genetic condition that causes fatal lung damage. |
Only about half of those with the condition live to the age of 40. | |
NHS England chief executive Simon Stevens said the deal was "good for patients and fair to British taxpayers". | NHS England chief executive Simon Stevens said the deal was "good for patients and fair to British taxpayers". |
Health Secretary Matt Hancock described it as "wonderful news". |